Shenzhen S.E.
03:30:00 31/05/2024 am IST
5-day change
1st Jan Change
27.58
CNY
-1.22%
-1.68%
+24.07%
Jafron Biomedical Co.,Ltd.'s Board intends to launch an Equity Buyback.
August 26, 2021 at 09:30 am IST
On August 26, 2021, the company announced that its Board of Directors will consider a share repurchase program. Under the program the company may repurchase CNY 500 million worth of its shares. The program will be valid for a period of 6 months.
Jafron Biomedical Co.,Ltd. Announces Final Dividend on A Shares for 2023, Payable on 31 May 2024
25/05
CI
Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023
27/04
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
25/04
CI
Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.
03/04
CI
Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.
03/04
CI
Jafron Biomedical Co.,Ltd.'s Equity Buyback announced on July 17, 2023, has closed with 24,242,904 shares, representing 3% for CNY 500 million.
03/04
CI
Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.
02/01
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
27/23/27
CI
Zhuhai Jianfu Pharmaceutical Co., Ltd. announced that it expects to receive CNY 15 million in funding from Jafron Biomedical Co.,Ltd.
23/23/23
CI
Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.
13/23/13
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
18/23/18
CI
Jafron Biomedical Co.,Ltd. announces an Equity Buyback for CNY 500 million worth of its shares.
17/23/17
CI
Jafron Biomedical Co.,Ltd. authorizes a Buyback Plan.
17/23/17
CI
Jafron Biomedical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on 31 May 2023
25/23/25
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
27/23/27
CI
Jafron Biomedical Co.,Ltd. Approves the Cash Dividend for 2022
25/23/25
CI
Jafron Biomedical Co.,Ltd. Approves Director Elections
25/23/25
CI
Jafron Biomedical Co.,Ltd. Announces Profit Distribution Proposal for 2022
01/23/01
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
30/23/30
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
27/22/27
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
25/22/25
CI
Jafron Biomedical Co.,Ltd. Implements Final Cash Dividend (A Shares) for 2021, Payable on 10 June 2022
06/22/06
CI
Jafron Biomedical Co.,Ltd. Approves Profit Distribution
17/22/17
CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
13/22/13
CI
Jafron Biomedical Boosts Final Dividend as 2021 Profit Surges 37%
13/22/13
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Jafron Biomedical Co.,Ltd. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Companyâs products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Companyâs products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Companyâs products are applied in 31 provinces, more than 3000 hospitals in China.
More about the company
Last Close Price
27.58
CNY
Average target price
33.94
CNY
Spread / Average Target
+23.08%
Consensus
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
JAFRON BIOMEDICAL CO.,LTD. 
